Summary
3.09
-0.11
(-3.44%)
05/15/2026
Cellectar Biosciences, Inc. (CLRB)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -3.44 | 0.98 | 1.64 | -0.96 | 5.82 | -59.40 | -99.20 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | B- |
| Recommended Rating | Sell |
| DCF | Buy |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Neutral |
| P/E | Strong Sell |
| P/B | Buy |
Earnings
| Trading Data | ||
| Close | 3.09 | |
| Open | 3.26 | |
| High | 3.26 | |
| Low | 2.99 | |
| Volume | 216,322 | |
| Change | -0.11 | |
| Change % | -3.44 | |
| Avg Volume (20 Days) | 2,975,684 | |
| Volume/Avg Volume (20 Days) Ratio | 0.07 | |
| 52 Week Range | 2.43 - 20.59 | |
| Price vs 52 Week High | -84.99% | |
| Price vs 52 Week Low | 27.16% | |
| Range | -5.21 | |
| Gap Up/Down | -0.04 | |
Profitibility | ||
| Market Capitalization (Mln) | 11 | |
| Revenue per share | 0.0000 | |
| Net Income per share | -4.9152 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -0.6287 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
05/14 11:50 EST - seekingalpha.com
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
05/14 07:15 EST - globenewswire.com
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM)
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM)
05/11 08:05 EST - globenewswire.com
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the...
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the...
05/07 13:00 EST - zacks.com
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
05/06 09:17 EST - benzinga.com
What's Going With Cellectar Biosciences Stock On Wednesday?
Cellectar Biosciences Inc (NASDAQ:CLRB) shares are down during Wednesday's premarket session after the stock closed almost 12% higher on Tuesday after positive clinical trial data and financing efforts.
What's Going With Cellectar Biosciences Stock On Wednesday?
Cellectar Biosciences Inc (NASDAQ:CLRB) shares are down during Wednesday's premarket session after the stock closed almost 12% higher on Tuesday after positive clinical trial data and financing efforts.
05/05 09:50 EST - benzinga.com
Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses
Cellectar Biosciences, Inc. (NASDAQ:CLRB) shares are up during Tuesday's trading session as the company announced promising results from its Phase 2b CLOVER WaM clinical trial.
Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses
Cellectar Biosciences, Inc. (NASDAQ:CLRB) shares are up during Tuesday's trading session as the company announced promising results from its Phase 2b CLOVER WaM clinical trial.
05/05 07:10 EST - globenewswire.com
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response of 17.8 months FDA-requested dataset with ≥12-month follow-up on all patients strengthens regulatory positioning for accelerated approval and supports initiation of confirmatory trial in 4Q26...
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response of 17.8 months FDA-requested dataset with ≥12-month follow-up on all patients strengthens regulatory positioning for accelerated approval and supports initiation of confirmatory trial in 4Q26...
05/05 07:00 EST - globenewswire.com
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
Oversubscribed Financing Led by Nantahala Capital with Participation from Balyasny Asset Management, Caligan Partners, Janus Henderson Investors, SilverArc Capital Management, Stonepine Capital Management, Empery Asset Management LP, StemPoint Capital LP and other Dedicated Healthcare Funds along...
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
Oversubscribed Financing Led by Nantahala Capital with Participation from Balyasny Asset Management, Caligan Partners, Janus Henderson Investors, SilverArc Capital Management, Stonepine Capital Management, Empery Asset Management LP, StemPoint Capital LP and other Dedicated Healthcare Funds along...
04/14 08:35 EST - globenewswire.com
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125 in refractory TNBC, to determine recommended Phase 2 dose Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125 in refractory TNBC, to...
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125 in refractory TNBC, to determine recommended Phase 2 dose Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125 in refractory TNBC, to...
03/04 11:42 EST - seekingalpha.com
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
03/04 07:15 EST - globenewswire.com
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia
02/25 08:05 EST - globenewswire.com
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the...
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the...
02/17 08:05 EST - globenewswire.com
Cellectar Biosciences Expands Global Intellectual Property Estate
Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing Approval with the European Medicines Agency (EMA) for Iopofosine I 131 as a Treatment for...
Cellectar Biosciences Expands Global Intellectual Property Estate
Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing Approval with the European Medicines Agency (EMA) for Iopofosine I 131 as a Treatment for...
01/09 08:05 EST - globenewswire.com
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
Following Guidance from the European Medicines Agency's (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom's Macroglobulinemia (WM), Expects to Submit for Conditional Marketing Approval in Europe in 3Q 2026
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
Following Guidance from the European Medicines Agency's (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom's Macroglobulinemia (WM), Expects to Submit for Conditional Marketing Approval in Europe in 3Q 2026
12/23 01:16 EST - defenseworld.net
Perrigo (NYSE:PRGO) & Cellectar Biosciences (NASDAQ:CLRB) Critical Survey
Cellectar Biosciences (NASDAQ: CLRB - Get Free Report) and Perrigo (NYSE: PRGO - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation,...
Perrigo (NYSE:PRGO) & Cellectar Biosciences (NASDAQ:CLRB) Critical Survey
Cellectar Biosciences (NASDAQ: CLRB - Get Free Report) and Perrigo (NYSE: PRGO - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation,...
12/16 08:05 EST - globenewswire.com
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors
11/13 15:41 EST - seekingalpha.com
Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript
Cellectar Biosciences, Inc. ( CLRB ) Q3 2025 Earnings Call November 13, 2025 8:30 AM EST Company Participants James Caruso - President, CEO & Director Chad Kolean - VP, CFO & Secretary Jarrod Longcor - Chief Operating Officer Conference Call Participants Anne Marie Fields Aydin Huseynov - Ladenburg...
Cellectar Biosciences, Inc. (CLRB) Q3 2025 Earnings Call Transcript
Cellectar Biosciences, Inc. ( CLRB ) Q3 2025 Earnings Call November 13, 2025 8:30 AM EST Company Participants James Caruso - President, CEO & Director Chad Kolean - VP, CFO & Secretary Jarrod Longcor - Chief Operating Officer Conference Call Participants Anne Marie Fields Aydin Huseynov - Ladenburg...
11/13 07:20 EST - globenewswire.com
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific Advice Working Party (SAWP)
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific Advice Working Party (SAWP)
10/14 08:30 EST - globenewswire.com
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft Models CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic...
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft Models CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic...
Market News
×
Loading news…